Offer for Students ₹ 999 INR ( offer valid till 31st December 2025)
71. Hemophilia in Children
Authors:
1. Bugubaeva Makhabat Mitalipovna
2. Saad Khan
(1. HOD Clinical Disciplines-2, Associate Professor, International Medical Faculty, Osh State University, Osh, Kyrgyzstan.
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyzstan.)
Abstract
Hemophilia is a hereditary bleeding disorder characterized by a deficiency or dysfunction of specific coagulation factors, resulting in a lifelong tendency toward excessive bleeding. In children, hemophilia presents unique diagnostic and management challenges due to its early onset, genetic nature, and long-term implications on physical and psychosocial health. This paper explores the genetic basis, pathophysiological mechanisms, clinical spectrum, diagnostic modalities, and therapeutic interventions for hemophilia in the pediatric population. It further reviews the evolution of hemophilia care, from plasma-derived factor concentrates to recombinant and gene therapy approaches, emphasizing early detection, prophylactic management, and multidisciplinary care to improve quality of life and long-term outcomes for affected children.
Keywords
Hemophilia, Children, Coagulation Disorders, Factor VIII, Factor IX, Genetics, Treatment, Prophylaxis, Gene Therapy.
Introduction
Hemophilia is a rare, X-linked inherited bleeding disorder that affects the body's ability to form stable blood clots. The disease primarily manifests in males, while females are typically carriers. Hemophilia results from deficiencies in clotting factor VIII (Hemophilia A) or factor IX (Hemophilia B). Both types lead to prolonged or spontaneous bleeding, especially into joints and muscles. In children, the early detection and management of hemophilia are vital to prevent long-term complications such as chronic arthropathy, disability, and psychosocial distress. The global burden of hemophilia continues to vary significantly, with resource-limited regions facing diagnostic and therapeutic challenges. Advancements in molecular genetics, factor replacement therapy, and prophylactic regimens have transformed hemophilia from a fatal condition to a manageable chronic disorder. This paper provides a comprehensive analysis of hemophilia in children, focusing on its genetics, pathogenesis, clinical course, diagnostic criteria, and modern therapeutic strategies.
Review of Literature
The history of hemophilia dates back to ancient times, with the first clear clinical descriptions emerging in the 19th century. Scientific understanding of hemophilia expanded in the 20th century with the identification of coagulation factor deficiencies. The separation of hemophilia into two major types—A and B—occurred in 1952 when Pavlovsky demonstrated that patients with hemophilia B (Christmas disease) had a different plasma defect than those with hemophilia A. Subsequent research revealed the genetic and molecular underpinnings of these disorders, including the mutations responsible for factor VIII and IX deficiencies. In the pediatric population, early studies emphasized the importance of early diagnosis and family screening. With the advent of factor concentrates and recombinant products, treatment outcomes improved dramatically. Recent decades have focused on gene therapy and personalized medicine, aiming to achieve a functional cure for hemophilia through long-term endogenous production of the deficient factor.
Epidemiology and Genetics
Hemophilia affects approximately 1 in 5,000 male births for Hemophilia A and 1 in 30,000 male births for Hemophilia B. It occurs worldwide and across all ethnic groups. The condition is inherited in an X-linked recessive manner, meaning that the defective gene is located on the X chromosome. Female carriers have a 50% chance of transmitting the mutated gene to their offspring—sons who inherit the gene are affected, while daughters become carriers. In about 30% of cases, hemophilia arises from spontaneous mutations with no prior family history. Genetic testing has enabled precise identification of mutations, allowing for prenatal diagnosis and carrier detection. Advances in next-generation sequencing technologies have also improved understanding of the molecular basis of hemophilia, including point mutations, deletions, and inversions in the F8 and F9 genes.
Pathophysiology and Classification
The coagulation cascade consists of a complex sequence of enzymatic reactions that culminate in the formation of a stable fibrin clot. In hemophilia, deficiencies of factor VIII or IX disrupt the intrinsic pathway, leading to insufficient generation of thrombin and unstable clot formation. Hemophilia A is due to deficiency of factor VIII, while hemophilia B results from deficiency of factor IX. Both disorders share similar clinical manifestations but differ in molecular genetics. The severity of hemophilia depends on the residual activity of the deficient factor: severe (<1% activity), moderate (1–5%), or mild (6–40%). Severe hemophilia typically manifests early in childhood, often during infancy, with spontaneous bleeding episodes or excessive bleeding following minor trauma. The impaired clotting mechanism results in prolonged bleeding times, recurrent hemarthroses, and progressive joint destruction.
Clinical Manifestations
The clinical presentation of hemophilia in children varies according to disease severity. In severe cases, spontaneous bleeding can occur within the first year of life. Common manifestations include prolonged bleeding after circumcision, vaccinations, or minor injuries. Recurrent joint bleeding (hemarthrosis) is the hallmark of severe hemophilia, most often affecting the knees, ankles, and elbows. Repeated episodes lead to chronic synovitis and hemophilic arthropathy. Muscle hematomas, epistaxis, gastrointestinal bleeding, and intracranial hemorrhage are also frequent. Children who suffer from moderate or mild forms of inherited or acquired bleeding disorders often present a significant diagnostic challenge for clinicians. Because the deficiency or dysfunction in their clotting mechanism is not severe enough to cause spontaneous, noticeable bleeding early in life, these conditions may not be diagnosed during childhood or adolescence. Consequently, the true nature of their underlying hemostatic defect might only become apparent much later in life. The disorder is typically discovered only when the patient experiences a substantial challenge to their clotting system, such as during an elective or emergency surgical procedure or following significant physical trauma, at which point excessive and uncontrollable bleeding occurs..
Diagnostic Approaches
The diagnosis of hemophilia involves a combination of clinical evaluation and laboratory testing. Initial screening tests include prolonged activated partial thromboplastin time (aPTT) with normal prothrombin time (PT) and bleeding time. Confirmatory assays for specific factor levels (VIII or IX) establish the diagnosis and determine disease severity. Molecular genetic testing identifies carrier status and assists in prenatal diagnosis. Advanced techniques such as next-generation sequencing have facilitated the identification of novel mutations, aiding genetic counseling and family planning. In resource-limited settings, diagnosis may rely primarily on clinical suspicion and basic coagulation studies, emphasizing the need for capacity building in laboratory diagnostics.
Management and Therapeutic Advances
The management of hemophilia in children aims to prevent and control bleeding, preserve joint function, and enhance quality of life. Treatment is primarily based on replacement therapy with clotting factor concentrates—either plasma-derived or recombinant. Prophylactic infusions are preferred in children with severe hemophilia to prevent spontaneous bleeds and arthropathy. Adjunctive therapies include antifibrinolytic agents, desmopressin (for mild Hemophilia A), and physiotherapy. The development of inhibitors—neutralizing antibodies against infused factors—remains a major challenge, necessitating immune tolerance induction protocols. Recent advances include extended half-life factor products that reduce infusion frequency and gene therapy approaches offering long-term endogenous factor expression. Multidisciplinary care involving hematologists, physiotherapists, dentists, and psychologists ensures optimal outcomes for pediatric patients.
Complications and Prognosis
The major complications of hemophilia in children include joint damage, muscle contractures, and inhibitor development. Repeated joint hemorrhages lead to chronic pain, deformity, and disability. Inhibitor formation, occurring in up to 30% of patients with severe Hemophilia A, complicates treatment by rendering factor replacement ineffective. In the past, transmission of blood-borne infections such as HIV and hepatitis was a major concern, though modern recombinant therapies have virtually eliminated this risk. With appropriate prophylaxis and comprehensive care, life expectancy for children with hemophilia now approaches that of the general population. Early diagnosis, consistent treatment adherence, and access to multidisciplinary care are key determinants of long-term prognosis.
Discussion
The management of hemophilia has evolved dramatically over the past few decades. Once considered a fatal childhood disease, it is now a manageable chronic condition with a near-normal lifespan. One of the most significant changes is the widespread adoption and early initiation of prophylaxis. Prophylaxis involves the regular, scheduled infusion of deficient clotting factors before a bleed occurs. This proactive approach has dramatically shifted the management paradigm from treating acute bleeding episodes to actively preventing them. By starting this preventative treatment early in childhood, physicians are now successfully able to minimize joint damage, reduce the risk of life-threatening hemorrhages, and thereby enable children to enjoy a far higher quality of life with greater mobility and fewer complications than previous generations. However, disparities persist between developed and developing countries in terms of diagnosis, access to treatment, and patient education. Establishing national hemophilia registries, expanding access to recombinant products, and promoting awareness among healthcare professionals are essential to improve outcomes globally. Emerging therapies, including non-factor replacement treatments like emicizumab, offer additional hope for simplifying management and enhancing patient adherence.
Conclusion
Hemophilia in children represents a complex but increasingly manageable bleeding disorder. Through advances in genetics, diagnostics, and therapeutics, significant improvements have been achieved in morbidity, mortality, and quality of life. The future of hemophilia care lies in individualized medicine, gene therapy, and equitable access to treatment across all regions. The future well-being and life expectancy of children affected by hemophilia are critically dependent upon ongoing research efforts. Continuous scientific investigation into the underlying genetics, pathophysiology, and innovative therapeutic strategies is vital. These dedicated research initiatives aim to unlock more effective and potentially curative treatments, ultimately moving beyond current standard-of-care factor replacement to offer superior long-term outcomes and minimize the debilitating effects of recurrent bleeding episodes.
References
1. Srivastava A, Santagostino E, Dougall A, et al. (2020). WFH Guidelines for the Management of Hemophilia, 3rd Edition. Haemophilia, 26(S6), 1–158.
2. Peyvandi F, Garagiola I, Young G. (2016). The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet, 388(10040), 187–197.
3. World Federation of Hemophilia. (2022). Annual Global Survey Report.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. (2007). Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. NEJM, 357(6), 535–544.
5. Pipe SW. (2022). Gene therapy for hemophilia: moving toward a functional cure. Hematology, 99(3), 1–9.
